DNA Script: Enzymatic DNA Synthesis and European Biological Sovereignty
Strategic mapping of DNA Script’s SYNTAX platform. Enabling rapid on-site DNA synthesis for sovereign biothreat detection, medical readiness, and DNA data storage.
14 pages · PDF · 28 December 2025 · Licensed single-user copy, watermarked to the buyer
€299 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
DNA Script SAS is a Paris-based deep-tech biotechnology company specializing in enzymatic DNA synthesis . Founded in 2014, it has developed the SYNTAX® platform, the world’s first benchtop DNA “printer,” enabling rapid on-site production of custom oligonucleotides for research and diagnostics.
Headquartered in Le Kremlin-Bicêtre (Paris metropolitan area) , DNA Script maintains additional operations in the United States (South San Francisco, California ) and a global distribution network (e.g. Middle East distributor in Dubai ). Its official website is dnascript.com (with active social media channels for press and support).
Key questions this report answers
- How does DNA Script's enzymatic DNA synthesis and the SYNTAX benchtop DNA printer enable rapid on-site production of custom oligonucleotides?
- What is the readiness of DNA Script's platform and its relevance to European biological sovereignty and dual-use biodefence?
- What is DNA Script's footprint (France HQ, US operations, global distribution network) and its partnerships and market strategy?
- What capability gaps, IP assets and strategic indicators shape DNA Script's contribution to European biotech autonomy?
Inside this report
- 2. Strategic Business Profile
- 3. Technology Portfolio Mapping
- 4. Technology Readiness Assessment
- 5. European Strategic Program Participation
- 6. Academic & Research Origins
- 7. Dual-Use Applications & European Market Strategy
- 8. Strategic Partnerships & European Industrial Alliances
- 9. European Market Focus & Operational Domains
- 10. Intellectual Property & European Innovation Assets
- 11. Leadership & European Technical Expertise
- 12. Capability and Gap Analysis
- 13. Strategic Indicators & European Innovation Metrics
- 14. Strategic Priority Alignment
Who it's for
Investors screening DNA Script SAS, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (28 December 2025). You receive a 14-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Synthetic Biology · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →